title: Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment.
abstract: BACKGROUND
  Chronic inflammatory demyelinating polyneuropathy (CIDP) as a pure sensory variant is rarely encountered. Therefore the best treatment option is hard to define.
  
  
  METHODS
  We reported two middle-aged patients of Caucasian origin, one female and one male, who over a period of several months presented limbs and gait ataxia. Clinical and neurophysiological examination revealed only sensory abnormalities. A diagnosis of atypical CIDP was suggested, considering the elevated CSF protein level and the presence of anti-gangliosides antibodies. Ten and 15 days respectively after initiation of prednisolone treatment both patients experienced exacerbation of sensory symptoms and emerging of muscle weakness. Steroids were then substituted by rituximab in the first patient and intravenous immunoglobulin in the second patient resulting in gradual decrement of symptoms and signs. Two-year follow-up showed no further deterioration.
  
  
  CONCLUSIONS
  Caution should be exercised when treating cases of pure sensory polyneuropathy with high dose steroids since an unfavorable outcome is possible.
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. echroni@yahoo.com.|Department of Neurology, University Hospital of Patras, Rion, 26504, Greece. echroni@yahoo.com.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Chroni
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. dveltsista@yahoo.gr.
authors.forename: Dimitra
authors.initials: D
authors.lastname: Veltsista
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. evigavanozi@yahoo.gr.
authors.forename: Evangelia
authors.initials: E
authors.lastname: Gavanozi
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. tavivlachou@yahoo.gr.
authors.forename: Tavitha
authors.initials: T
authors.lastname: Vlachou
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. ppolychr@yahoo.gr.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Polychronopoulos
authors.affiliation: Department of Neurology, School of Medicine, University of Patras, Patras, Greece. papat@upatras.gr.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Papathanasopoulos
mesh_terms: D018450:Disease Progression; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018908:Muscle Weakness / Q000139:chemically induced*; D009431:Neural Conduction; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D011239:Prednisolone / Q000009:adverse effects*; D000069283:Rituximab / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab; D011239:Prednisolone